Cancer Genomic Testing Market (2026-2036)

The global cancer genomic testing market is estimated to be USD 18.0 billion in 2026. This market is expected to reach USD 76.1 billion by 2036, growing at a CAGR of 15.5% during the forecast period 2026–2036. The growth of this market is driven by the increasing prevalence of cancer globally, the rising demand for precision medicine, advancements in next-generation sequencing (NGS) technologies, and favorable reimbursement policies for genomic testing in developed regions. Furthermore, the integration of artificial intelligence (AI) in genomic data interpretation and the growing number of FDA-approved companion diagnostics are expected to offer significant growth opportunities for market players.

The oncology landscape is undergoing a paradigm shift from traditional histopathology to molecular-driven diagnostics. Cancer genomic testing involves the comprehensive analysis of genetic alterations, including point mutations, insertions/deletions, copy number variations, and structural rearrangements. This molecular insight is fundamental to precision oncology, enabling clinicians to tailor therapeutic interventions based on the unique genomic signature of a patient's tumor. According to the World Health Organization (WHO), cancer remains a leading cause of death worldwide, with nearly 10 million deaths recorded in 2020. As the global cancer burden is projected to rise to 28.4 million cases by 2040, the demand for robust cancer sequencing and biomarker testing has become imperative for effective disease management.

Tumor genomic profiling has transitioned from research-only applications to routine clinical practice. The advent of Next-Generation Sequencing (NGS) has significantly reduced the cost and time required for whole-exome and whole-genome sequencing. The National Cancer Institute (NCI) emphasizes that genomic testing not only aids in therapy selection but also plays a critical role in clinical trial matching and identifying hereditary cancer syndromes. As precision oncology diagnostics become more accessible, the market is witnessing an influx of multi-gene panels and liquid biopsy assays that provide a non-invasive alternative to traditional tissue biopsies. The shift toward oncology genomics is further supported by the development of standardized reporting guidelines and the establishment of molecular tumor boards in leading cancer centers worldwide.

NGS cancer testing has revolutionized the diagnostic workflow by allowing for the simultaneous assessment of hundreds of genes. This high-throughput capability is essential for identifying actionable mutations in solid tumors and hematological malignancies. The integration of cancer biomarker testing into standard care pathways is being accelerated by the falling costs of sequencing and the increasing availability of targeted therapies. Industry associations like the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have incorporated genomic testing recommendations into their clinical practice guidelines, underscoring its clinical utility in improving patient survival rates.